NASDAQ: DRRX - DURECT Corporation

Rentabilität für sechs Monate: -30.15%
Sektor: Healthcare

Aktionsplan DURECT Corporation

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals.

weitere details
It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2000-09-28
ISIN US2666051048
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.durect.com
Цена ао 1.27
Preisänderung pro Tag: -1.87% (0.9681)
Preisänderung pro Woche: 0% (0.95)
Preisänderung pro Monat: +4.11% (0.9125)
Preisänderung über 3 Monate: -27.48% (1.31)
Preisänderung über sechs Monate: -30.15% (1.36)
Preisänderung pro Jahr: +61.02% (0.59)
Preisänderung über 3 Jahre: -0.2101% (0.952)
Preisänderung über 5 Jahre: -51.28% (1.95)
Preisänderung über 10 Jahre: 0% (0.95)
Preisänderung seit Jahresbeginn: +18.93% (0.7988)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 1.61 8
P/BV 0.9329 9
P/E 0 0
EV/EBITDA -0.167 0
Gesamt: 5.88

Effizienz

Name Bedeutung Grad
ROA, % -61.13 0
ROE, % -186.86 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.5647 10
Gesamt: 8

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % -71.12 0
Rentabilität Ebitda, % 36.38 5
Rentabilität EPS, % -18.62 0
Gesamt: 1.8
Weitere Details

Institutionen Volumen Aktie, %
Ingalls & Snyder 2146002 6.91
Vanguard Group Inc 1072489 3.46
Richmond Brothers, Inc. 518294 1.67
Gagnon Securities, LLC 358706 1.16
Blackrock Inc. 338855 1.09
Beirne Wealth Consulting Services, LLC 320051 1.03
Dalton Investments LLC 237334 0.76
Geode Capital Management, LLC 234364 0.76
Tocqueville Asset Management L.P. 231220 0.75
Ironwood Investment Management, LLC 195517 0.63



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. James E. Brown D.V.M. Co-Founder, CEO, President & Director 633.46k 1957 (68 Jahre)
Ms. Judy R. Joice Senior Vice President of Operations & Corporate Quality Assurance 451.82k 1957 (68 Jahre)
Dr. Norman L. Sussman M.D. Chief Medical Officer 471.71k 1953 (72 Jahr)
Mr. Timothy M. Papp M.B.A. CFO & Secretary 427.62k 1976 (49 Jahre)
Ms. Jian Li M.B.A. Senior VP of Finance, Corporate Controller & Secretary 297.08k 1970 (55 Jahre)
Dr. WeiQi Lin M.D., Ph.D. Executive VP of Research & Development and Principal Scientist N/A
Mr. Keith L. Lui M.B.A. Senior Vice President of Business Development, Commercial & Medical Affairs N/A
Dr. Su Il Yum Ph.D. Executive Officer 331.74k 1939 (86 Jahre)

Adresse: United States, Cupertino. CA -, 10260 Bubb Road - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.durect.com